<DOC>
	<DOCNO>NCT01479127</DOCNO>
	<brief_summary>To explore safety , tolerability , pharmacokinetics efficacy ABT-SLV187 advance Parkinson 's disease ( PD ) patient severe motor complication . The complication medical device naso-jejunum ( NJ ) infusion system ABT-SLV187 also investigate .</brief_summary>
	<brief_title>Study Safety , Tolerability , Pharmacokinetics , Efficacy ABT-SLV187 Subjects With Advanced Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Carbidopa</mesh_term>
	<mesh_term>Carbidopa , levodopa drug combination</mesh_term>
	<mesh_term>Levodopa</mesh_term>
	<mesh_term>Silicon</mesh_term>
	<criteria>Idiopathic PD accord United Kingdom Parkinson 's Disease Society ( UKPDS ) Brain Bank criterion PD stage correspond 4 5 'off ' state accord modify Hoehn &amp; Yahr ( H &amp; Y ) classification disease severity Levodoparesponsive subject demonstrate identifiable 'ON response ' establish observation Investigator demonstrate severe motor fluctuation spite individually optimize treatment therapy option indicate Diagnosis unclear suspicion parkinsonian syndrome exist secondary parkinsonism Undergone surgery treatment PD Contraindications levodopa Subjects neurological deficit may interfere study assessment</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Levodopa-carbidopa intestinal gel</keyword>
	<keyword>Advanced Parkinson 's disease</keyword>
	<keyword>Severe motor fluctuation</keyword>
	<keyword>Dyskinesia</keyword>
</DOC>